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An intriguing new clinical entity characterized by ST-segment elevation in the right
precordial electrocardiographic leads and a high incidence of sudden death in individuals with
structurally normal hearts was described by Pedro and Josep Brugada in 1992. The past
decade has witnessed an exponential rise in the number of reported cases and a dramatic
proliferation of papers serving to define the clinical, genetic, cellular, ionic, and molecular
aspects of this disease. The purpose of this brief review is to chronicle the historical highlights
that have brought us to our present understanding of Brugada syndrome. (J Am Coll
Cardiol 2003;41:1665–71) © 2003 by the American College of Cardiology Foundation
Evolution of a new clinical entity responsible for sudden
cardiac death: Brugada syndrome. The first such case
brought to the attention of the Brugada brothers involved a
three-year-old boy from Poland who presented in 1986
following multiple episodes of syncope. His electrocardio-
gram (ECG) showed ST-segment elevation limited to leads
V1 through V3. His sister displayed a similar clinical and
ECG profile and died at two years of age, despite combined
treatment with a pacemaker and amiodarone. Six similar
cases came to their attention in succeeding years, and in
1992, they reported these eight cases as the basis for a new
and distinct clinical entity (1).
In 1996, Yan and Antzelevitch (2), in their description of
the cellular basis for the J-wave of the ECG, highlighted the
importance of ST-segment elevation (accentuated J-wave)
and apparent right bundle branch block (RBBB) syndrome,
described by Brugada and Brugada, and named it the
“Brugada syndrome.” Kobayashi et al. (3) and Miyazaki et
al. (4) followed suit that same year.
The ECG pattern of ST-segment elevation and inversion
of the T-wave in the right precordial leads (Fig. 1), with and
without RBBB, was described as early as 1953 (5). This
ECG phenomenon was largely ignored until Martini et al.
in 1989 (6) and Aihara et al. (7) in 1990 brought attention
to a possible link between this ventricular repolarization
abnormality and sudden death. It is noteworthy that the
Padua group (6) described only one patient with the typical
Brugada ECG (Patient no. 3). Two others displayed RBBB
without ST-segment elevation, another showed an rsR’ with
barely detectable ST-segment elevation, and the rest
showed only inverted T waves. In this publication, as in
subsequent ones, the Padua group emphasized the anatomic
abnormalities, however subtle, attempting to link these and
similar cases to arrhythmogenic right ventricular dysplasia/
cardiomyopathy (ARVD/C).
Whereas Martini et al. (6) maintain that structural or
morphologic defects are involved, Brugada et al. exclude
these from the diagnosis, stressing the functional basis for
the syndrome. In 2001, Corrado et al. (8) elegantly de-
scribed a subpopulation of ARVC patients displaying fea-
tures of Brugada syndrome, including ST-segment elevation
in leads V1 through V3 and polymorphic ventricular tachy-
cardia (VT). This study clearly suggested that a subgroup of
ARVC patients can display a Brugada-like phenotype dur-
ing the relatively early stages of the disease.
The ARVD/C and Brugada syndromes are quite distinct
genetically. Brugada syndrome has thus far been linked only
to mutations in SCN5A, the gene encoding for the alpha-
subunit of the sodium channel, whereas ARVD/C has been
linked to seven different chromosomal sites and three
putative genes (9). In a recent study of a large group of
Brugada patients, Remme et al. (10) reported that the vast
majority of patients showed no evidence of structural
disease. Subsequent follow-up uncovered ARVC in only
one patient (11).
Using electron beam computed tomography, Takagi et al.
(12) recently demonstrated wall motion abnormalities in the
right ventricular outflow tract (RVOT) (n  17) and
inferior wall (n 4) in 21 of 26 Brugada patients. Although
wall motion abnormalities are commonly considered indic-
ative of structural problems, recent studies (13,14) suggest
that such contractile dysfunction can result from a loss of
the action potential dome in regions of right ventricular
(RV) epicardium, unrelated to any type of morphologic
defect.
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Also pertinent to this issue is the finding that signal-
averaged electrocardiogram (SAECG) recordings demon-
strate late potentials in patients with Brugada syndrome,
especially in the anterior wall of the RVOT (15,16). Nagase
et al. (17) recently recorded delayed potentials from the
epicardial surface of the anterior wall of the RVOT, coinciding
with late potentials on the SAECG, in patients with Brugada
syndrome. Although late potentials are commonly regarded as
representative of delayed activation of the myocardium, often
due to structural defects, recent studies suggest that in the case
of Brugada syndrome, these late and delayed potentials may
represent the delayed second upstroke of the epicardial action
potential or local phase 2 reentry (14).
Abbreviations and Acronyms
ARVD/C  arrhythmogenic right ventricular dysplasia/
cardiomyopathy
ECG  electrocardiogram/electrocardiographic
EPS  electrophysiologic study
ICD  implantable cardioverter-defibrillator
INa  sodium channel current
Ito  transient outward current
RBBB  right bundle branch block
RV  right ventricle/ventricular
RVOT  right ventricular outflow tract
SAECG  signal-averaged electrocardiogram
VF  ventricular fibrillation
VT  ventricular tachycardia
Figure 1. Precordial leads of a patient with Brugada syndrome. Note the dynamic electrocardiographic (ECG) changes in the course of a week. Three
distinct patterns are apparent. Arrows denote the J-wave. The left panel shows a type 1 ECG, whereas the middle and right panels depict type 2 and
3 Brugada ECGs. Reproduced from reference 39, with permission.
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Genetic aspects. The familial nature of the syndrome soon
became evident, and an autosomal mode of transmission
was demonstrated. Chen et al. (18) were the first to link the
syndrome to the alpha-subunit of the cardiac sodium
channel gene, SCN5A, in 1998. Nearly five dozen muta-
tions in SCN5A have been linked to the syndrome over the
past four years (19–21). Approximately two dozen of these
mutations have been studied in expression systems and have
been shown to result in a loss of function due to either: 1)
a failure of the sodium channel current (INa) to express; 2)
a shift in the voltage- and time-dependent INa activation,
inactivation, or reactivation; 3) entry of INa into an inter-
mediate state of inactivation from which it recovers more
slowly; or 4) accelerated inactivation of INa. This last
mechanism involving premature closure of the sodium
channel was observed at physiologic temperatures, but not
at room temperature (22). Because this characteristic of the
mutant channel was exaggerated at temperatures above the
physiologic range, we suggested that the syndrome may be
unmasked, and that patients with Brugada syndrome may
be at an increased risk during a febrile state (22). A number
of Brugada patients displaying fever-induced polymorphic
VT have been identified since the publication of this report
(23). Earlier this year, another locus on chromosome 3,
close to but distinct from SCN5A, was linked to the
syndrome (24). Brugada syndrome in this single, large
pedigree was associated with progressive conduction disease,
a low sensitivity to procainamide, and a relatively good
prognosis.
Cellular mechanisms. The cellular mechanisms believed
to underlie Brugada syndrome evolved on a parallel but
separate track from that of the clinical syndrome. The
concepts of all-or-none repolarization of the ventricular
epicardial action potential and of phase 2 reentry were
developed in the early 1990s (25–27). It was on a bus ride to
the airport following a meeting of the International Society
of Computerized Electrocardiography (ISCE) in Florida
that Dr. Antzelevitch, fortuitously seated next to Dr.
Phillipe Coumel, expressed surprise that there was appar-
ently no clinical counterpart to phase 2 reentry as a mech-
anism of arrhythmogenesis. After some discussion, Dr.
Coumel suggested that Dr. Antzelevitch contact the Bru-
gada brothers, who had recently described a syndrome with
somewhat similar characteristics. The rest, as they say, is
history. Drs. Antzelevitch, Pedro, Josep, and Ramon Bru-
gada, Jeffrey Towbin, and Kolawanee Nademanee have
worked as a cohesive team since the mid 1990s.
Basic studies conducted over the past dozen years suggest
that a rebalancing of the currents active at the end of phase
1, leading to an accentuation of the action potential notch in
the RV epicardium, is responsible for the accentuated J wave
or ST-segment elevation associated with Brugada syndrome
(19). In larger mammals, the presence of a transient outward
current (Ito)-mediated spike and dome morphology, or
notch, in the ventricular epicardium, but not in the endo-
cardium, creates a transmural voltage gradient responsible
for the inscription of the ECG J-wave (Fig. 2A) (2,28). The
ST-segment is isoelectric because of the absence of trans-
mural voltage gradients at the level of the action potential
plateau. Accentuation of the RV notch under pathophysi-
ologic conditions leads to exaggeration of transmural voltage
gradients and thus to accentuation of the J-wave or J-point
elevation. This would be expected to give rise to a saddle-
back configuration of the repolarization waves. The devel-
opment of a prominent J-wave under these conditions is
indistinguishable from ST-segment elevation. Under these
conditions, the T-wave remains positive because epicardial
repolarization precedes repolarization of the cells in the M
and endocardial regions. Further accentuation of the notch
may be accompanied by a prolongation of the epicardial
action potential, such that the direction of repolarization
across the RV wall and transmural voltage gradients are
reversed, leading to the development of a coved-type ST-
segment elevation and inversion of the T-wave, typically
observed on the ECG of Brugada patients (Fig. 2B). A
delay in epicardial activation may also contribute to inver-
sion of the T-wave. The downsloping ST-segment eleva-
tion, or accentuated J-wave, observed in the experimental
wedge models often appears as an R’, suggesting that the
appearance of RBBB morphology in Brugada patients may
be at least partly due to early repolarization of the RV
epicardium, rather than to impulse conduction block in the
right bundle. Indeed, a rigorous application of RBBB
criteria reveals that a large majority of RBBB-like morphol-
ogies encountered in cases of Brugada syndrome do not fit
the criteria for RBBB (29). Moreover, attempts by Miyazaki
et al. (4) to record delayed activation of the RV in Brugada
patients met with failure. It is noteworthy that despite the
appearance of a typical Brugada sign, the electrophysiologic
changes shown in Figure 2B do not give rise to an
arrhythmogenic substrate. We believe that the arrhythmo-
genic substrate develops with a further shift in the balance of
current leading to a loss of the action potential dome at
some epicardial sites but not in others (Fig. 2C). A loss of
the action potential dome in the epicardium but not in the
endocardium results in the development of a marked trans-
mural dispersion of repolarization and refractoriness, re-
sponsible for the development of a vulnerable window
during which a premature impulse or extrasystole can induce
a reentrant arrhythmia. A loss of the action potential dome
in the epicardium is usually heterogeneous, leading to the
development of epicardial dispersion of repolarization.
Conduction of the action potential dome from sites at
which it is maintained to sites at which it is lost causes local
re-excitation via a phase 2 reentry mechanism (Fig. 2D),
leading to the development of a very closely coupled
extrasystole, which captures the vulnerable window across
the wall, thus triggering a circus movement reentry in the
form of VT or ventricular fibrillation (VF) (30,31). The
phase 2 reentrant beat fuses with the negative T-wave of the
basic response. Because the extrasystole originates in the
epicardium, the QRS complex is largely comprised of a
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Q-wave, which serves to accentuate the negative deflection
of the inverted T-wave, giving the ECG a more symmet-
rical appearance. This morphology is often observed in the
clinic preceding the onset of polymorphic VT. Support for
these hypotheses is derived from experiments involving the
arterially perfused RV wedge preparation (31) and from
recent studies in which monophasic action potential electrodes
were positioned on the epicardial and endocardial surfaces of
the RVOT in a patient with Brugada syndrome (32,33).
One of the intriguing aspects of Brugada syndrome is that
despite equal genetic transmission of the disease, the clinical
phenotype is 8 to 10 times more prevalent in males than in
females. The basis for this gender-related distinction was
recently shown to be due to a more prominent Ito-mediated
action potential notch in the RV epicardium of males versus
females (34). As a result, the end of phase 1 of the RV
epicardial action potential was more negative in tissue and
arterially perfused wedge preparations from males, facilitat-
ing a loss of the action potential dome and the development
of phase 2 reentry and polymorphic VT.
Diagnostic criteria. ST-segment elevation is associated
with a wide variety of benign as well as malignant patho-
physiologic conditions. A differential diagnosis is difficult at
times, particularly when the degree of ST-segment elevation
is relatively small and the specificity of sodium channel
blockers (e.g., flecainide, ajmaline, procainamide, disopyr-
amide, propafenone, pilsicainide) (35–37) to identify pa-
tients at risk is uncertain. A consensus report recently
published by the Arrhythmia Working Group of the Euro-
pean Society of Cardiology addresses these and other
ambiguities concerning the diagnostic criteria for Brugada
syndrome (38,39).
Clinical characteristics. Although long suspected, it was
only recently definitively shown that sudden unexplained
death syndrome, a disorder most prevalent in southeast
Asia, and Brugada syndrome are phenotypically, genetically,
and functionally the same disorder (40). Sudden and unex-
pected death of young adults during sleep, known in the
Philippines as bangungut (“to rise and moan in sleep”), was
first described in the Philippine medical literature in 1917.
Figure 2. Schematic representation of right ventricle epicardial action potential (AP) changes thought to underlie the electrocardiographic (ECG)
manifestation of Brugada syndrome. Modified from reference 28, with permission.
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In 1948, the Honolulu Medical Examiner reported a series
of 81 similar deaths of Philippine men in Oahu County
(41). In Japan this syndrome, known as pokkuri (“sudden
and unexpectedly ceased phenomena”), was reported as early
as 1959 (42). In 1997, Nademanee et al. (43) reported that
among 27 Thai men referred for aborted cases of what was
known in Thailand as Lai Tai (“death during sleep”), as
many as 16 had the ECG pattern of Brugada syndrome.
When Alings and Wilde (44) reviewed the literature in
1999, they found that of the 163 patients who met the
criteria for Brugada syndrome, 58% were of Asian origin.
In the span of 10 years, the syndrome has gained wide
recognition throughout the world and today is believed to be
responsible for 4% to 12% of all sudden deaths and 20%
of deaths in patients with a structurally normal heart. The
incidence of the disease is on the order of 5 per 10,000
inhabitants and, apart from accidents, is the leading cause of
death of men under the age of 40 years in regions of the
world where the syndrome is endemic.
In addition to sodium channel blockers and a febrile state,
vagotonic agents, alpha-adrenergic agonists, beta-adrenergic
blockers, tricyclic antidepressants, first-generation antihis-
tamines (dimenhydrinate), and cocaine toxicity have been
shown to unmask Brugada syndrome or to accentuate
ST-segment elevation in patients with the syndrome
(4,35,45–51). Like the long QT syndrome, Brugada syn-
drome has both congenital and acquired forms; the latter is
just beginning to be appreciated.
Identification of patients at risk of sudden death has been
a primary goal of research teams worldwide (20,52). Pa-
tients initially presenting with aborted sudden death are at
the highest risk for a recurrence (69%), whereas those
presenting with syncope and a spontaneously appearing
Brugada ECG sign have a recurrence rate of 19%. The study
by Brugada et al. (52) found an 8% occurrence of cardiac
events in initially asymptomatic patients. Asymptomatic
patients at highest risk were those who displayed the
Brugada sign spontaneously; those in whom ST-segment
elevation appeared only after provocation with sodium
channel blockers appeared to be at minimal or no risk for
arrhythmic events. Of the 667 patients with the Brugada
phenotype seen by Pedro and Josep Brugada, those at
highest risk were males with inducible VT and a spontane-
ously elevated ST-segment. However, controversy exists
regarding the role of electrophysiologic study (EPS) in
identifying high-risk patients.
The study by Brugada et al. (52) also suggested that
among asymptomatic patients, inducibility of VT during
EPS may be prognostic of risk. Studies by Priori et al. (20),
Kanda et al. (53), and Eckardt et al. (54) failed to find an
association between inducibility and recurrence of VT/VF
among Brugada patients (both asymptomatic and symptom-
atic). These discrepancies may be a consequence of several
confounding variables. For example, Kanda et al. (53) had
no asymptomatic patients in their study, and the number of
asymptomatic patients in Priori et al.’s study (20) was
relatively small; 14 patients were not inducible (1 patient
had a subsequent cardiac event [8%]) and 35 patients were
inducible (3 patients had an event [8%]). Moreover, both
the studies by Brugada et al. (1,35,45,52,55–57) and Priori
et al. (20,37) involved multiple electrophysiology centers
with nonstandardized stimulation protocols. All studies
clearly showed that symptomatic patients have a much
higher risk of sudden death than asymptomatic patients.
However, the overall 8% event rate in young asymptomatic
individuals with the Brugada ECG pattern is too high to
ignore. Additional studies are needed to further define the
evolving therapeutic approach for asymptomatic patients.
Meanwhile, we recommend, based on the current available
data, that symptomatic patients with the Brugada pattern
(aborted sudden cardiac death or syncope) should have an
implantable cardioverter-defibrillator (ICD), regardless of
the EPS finding. Asymptomatic patients, however, should
undergo EPS, and, if inducible, ICD implantation is rec-
ommended. As more data become available, the role of EPS
in risk stratification of Brugada syndrome patients may have
to be modified or abandoned. At the present, however, we
believe that it should remain an integral part of our search
for high-risk asymptomatic individuals.
Advances in therapy. Although great progress has been
achieved in the identification and characterization of Bru-
gada syndrome over the past decade, relatively little progress
has been made in the approach to therapy. Table 1 lists the
various device and pharmacologic therapies that have been
tested clinically or suggested based on experimental evi-
dence. Implantation of an ICD is the only established
effective treatment for the disease (55,56). However, this is
not the optimal solution for infants and young children or
for adults residing in regions of the world where an ICD is
unaffordable. The role of pacemaker therapy is largely
unexplored. Arrhythmias and sudden death generally occur
during sleep or at rest and are commonly associated with
bradycardic states, suggesting a potential therapeutic role for
pacing.
The need for cost-effective treatment or preventative
Table 1. Device and Pharmacologic Considerations for Therapy
in Brugada Syndrome
Devices
 ICD—only established effective therapy
? Pacemaker
Pharmacologic
X Amiodarone—does not protect (57)
X Beta-blockers—does not protect (57)
 Beta-adrenergic agonists—isoproterenol (4, 60)
 Phosphodiesterase inhibitors—cilostazol (65)
X Class IC anti-arrhythmics—flecainide and propafenone
contraindicated
Class IA anti-arrhythmics
X Procainamide and disopyramide contraindicated
 Quinidine (31, 59, 63, 64)
? Tedisamil
 Ito blockers—cardioselective and ion channel specific
ICD  implantable cardioverter-defibrillator; Ito  transient outward current.
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measures is evident. The pharmacologic approach to ther-
apy has been geared to a rebalancing of currents active
during the early phases of the RV epicardial action poten-
tial, so as to reduce the magnitude of the action potential
notch and/or restore the action potential dome. Anti-
arrhythmic agents such as amiodarone and beta-blockers
have been shown to be ineffective (57). Class IC anti-
arrhythmic drugs such as flecainide and propafenone are
clearly contraindicated for reasons previously discussed.
Class IA agents such as procainamide and disopyramide are
contraindicated for similar reasons. Other class IA agents
such as quinidine and tedisamil may exert a therapeutic
action, however. Because the presence of a prominent Ito is
at the heart of the mechanism underlying Brugada syn-
drome, any agent that blocks this current is likely to be
protective. Regrettably, cardioselective and Ito-specific
blockers are not currently available. The only agent on the
market in the U.S. with significant Ito-blocking properties is
quinidine. It is for this reason that we suggested several
years ago that this agent may be of therapeutic value in
Brugada syndrome (58). Experimental studies have since
shown quinidine to be effective in restoring the epicardial
action potential dome, thus normalizing the ST-segment
and preventing phase 2 reentry and polymorphic VT in
experimental models of Brugada syndrome (31). Agents
that boost the calcium current, such as isoproterenol, may be
useful as well (19,31). Both types of agents have been shown
to be effective in normalizing ST-segment elevation in
patients with Brugada syndrome and in controlling electrical
storms, particularly in children (59–63). Other than the
studies by Belhassen et al. (63,64) involving quinidine, none
have yet demonstrated long-term efficacy in the prevention
of sudden death. The most recent addition to the pharma-
cologic armamentarium is the phosphodiesterase III inhib-
itor cilostazol (65), which normalizes the ST-segment most
likely by reducing Ito secondary to an increase in heart rate,
as well as by augmenting the calcium current. Finally, an
experimental anti-arrhythmic agent, tedisamil, with potent
actions to block Ito, among other outward currents, has been
suggested as a therapeutic candidate (19). Tedisamil may be
more potent than quinidine because it lacks the relatively
strong inward current blocking actions of quinidine. The
development of a cardioselective and Ito-specific blocker
would be a most welcome addition to the limited therapeu-
tic armamentarium currently available to combat this dis-
ease, and appropriate clinical trials are needed to establish
the effectiveness of all of the aforementioned pharmacologic
agents, as well as the possible role of pacemakers.
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